Australia & New Zealand Healthcare CROs Market To Reach $3.35 Billion By 2033

Australia & New Zealand Healthcare CROs Market Growth & Trends

The Australia & New Zealand healthcare CROs market size is estimated to reach USD 3.35 billion by 2033, registering a CAGR of 11.02% from 2025 to 2033, according to a new report by Grand View Research, Inc. The rising costs associated with drug development are anticipated to drive the demand. As clinical trial costs continue to increase and challenges related to patient recruitment persist, biopharmaceutical companies are increasingly turning to countries such as Australia, New Zealand, China, and India in search of cost savings and efficient patient recruitment. As a result, the market is expected to benefit from this trend over the forecast period.

R&D tax credits are available in both countries. According to the April 2021 update from Brandon Capital Partners, a key Australasian life sciences venture capital firm, the R&D tax incentive given to international sponsors in Australia can lead to savings in costs of up to 43.5%, in comparison to New Zealand's 15%. In addition, the article stated that the Australian government projected that its tax credit helped the clinical trial sector reach a value of USD 1 billion, which would eventually boost the Australia and New Zealand contract research organizations industry’s growth.

The growing adoption of digital health technologies, such as telemedicine, wearables, and AI, is impacting drug development & clinical trials, creating new opportunities for contract research organizations. Australia is one of the leading countries to conduct decentralized clinical trials; according to Novotech, During the COVID-19 pandemic, Australia demonstrated significant progress in online care platforms. From March 2020 to April 2021, more than 56 million telehealth services were provided to around 13.6 million patients. In addition, the government's recent 2021-2022 Federal Budget allocated an additional USD 204.6 million to telehealth, bringing the total investment to USD 3.6 billion.

 Request a free sample copy or view report summary: Australia & New Zealand Healthcare CROs Market Report

Australia & New Zealand Healthcare CROs Market Report Highlights

• Based on type, the clinical segment dominated the market in 2024, with the largest share of 75.93%, because it comprises four elaborate phases, including human subjects. The significant demand for new treatments has further contributed to the growth of the segment.

• Based on service, the regulatory/medical affairs service segment is expected to register the fastest CAGR over the forecast period.

• Based on the therapeutic area, the oncology segment accounted for the largest market share in 2024, owing to the increasing incidence of cancer, advancements in oncology research, and the growing demand for targeted therapies.

• Based on end-use, pharmaceutical companies segment accounted for the largest share in 2024, owing to rising R&D investments, increasing clinical trial complexity, and demand for innovative therapeutics.

Australia & New Zealand Healthcare CROs Market Segmentation

Grand View Research has segmented the Australia & New Zealand healthcare CROs market based on type, service, therapeutic area, and end-use:

Australia & New Zealand Healthcare CROs Type Outlook (Revenue, USD Million, 2021 - 2033)

• Drug Discovery

  • Target Validation

  • Lead Identification

  • Lead Optimization

• Pre-clinical

• Clinical

  • Phase I Trial Services

  • Phase II Trial Services

  • Phase III Trial Services

  • Phase IV Trial Services

Australia & New Zealand Healthcare CROs Service Outlook (Revenue, USD Million, 2021 - 2033)

• Project Management/Clinical Supply Management

• Data Management

• Regulatory/Medical Affairs

• Medical Writing

• Clinical Monitoring

• Quality Management/ Assurance

• Bio-statistics

• Investigator Payments

  • Laboratory

  • Sterility Testing

  • Container/Closure Testing

  • Extractables and Leachable Testing

  • Environmental Monitoring (Including Microbiology Testing)

  • Disinfectant Efficacy Studies

  • Others

• Patient And Site Recruitment

• Technology

• Others

Australia & New Zealand Healthcare CROs Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

• Oncology

• CNS Disorders

• Infectious Diseases

• Immunological Disorders

• Cardiovascular Diseases

• Respiratory Diseases

• Diabetes

• Ophthalmology

• Pain Management

• Others

Australia & New Zealand Healthcare CROs End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Pharmaceutical

• Small Molecules

• Biologics

• Medical Device

List of Key Players in the Australia & New Zealand Healthcare CROs Market

• PAREXEL International Corporation

• Thermo Fischer Scientific, Inc.

• SGS SA

• ICON plc

• Medpace Australia Pty. Ltd

• Charles River Laboratories International, Inc.

• IQVIA

• Novotech

• Laboratory Corporation of America Holdings

• Syneos Health